SEMA US teams in Lebanon have been treating children with thalassaemia. A genetic blood disorder, in its acute forms, thalassaemia requires intensive treatment that SEMA US provides in a pediatric clinic.
Thalassaemia is a hereditary disease caused by an alteration in the genes required to synthesise haemoglobin, the molecule that is responsible for carrying oxygen in the blood. Patients left untreated can have considerably shorter life expectancy. Treatment requires regular blood transfusions. However, this causes iron overload, leading to heart, liver and other diseases, so thalassaemia patients need iron chelation drugs.
It is a difficult disease for any child to live with. It requires recurrent admissions – sometimes three times per month, recurrent needle pricks, taking medications every day for the rest of their lives and living with the complications of the disease. Children with thalassaemia have to deal with the pressure of leading lives that are different in many ways from their peers’, and of learning to manage a chronic condition.
But living with thalassaemia is even harder for refugee children in Lebanon, where access to public healthcare is extremely limited.
COVID-19, Beirut explosion, makes treatment more difficult
The collapse of the Lebanese economy, compounded by the impact of the COVID-19 pandemic, has made it even more difficult for Syrian refugee families to access already overstretched public health services. The COVID-19 pandemic has impacted families of children with thalassaemia in many ways.
Free treatment for refugees and vulnerable Lebanese
Our program is providing free-of-charge, comprehensive care to children, whatever their nationality. Most of the child patients today are Syrian refugees, though some come from vulnerable Lebanese families.
With the economic collapse in Lebanon and the financial impact of the COVID-19 pandemic hitting vulnerable families the hardest, the need for the program to continue providing lifesaving care to these children is greater than ever.